Clinical validation of urinary Bcl-2 as a reliable biomarker for ovarian cancer was conducted with ELISA tests using urine samples collected from 388 patients, including healthy controls and patients with benign gynecological disorders, early- and late-stage ovarian cancer [18]. The gene discussed is BCL2; the disease is ovarian carcinoma.